Atzumi is a drug owned by Satsuma Pharmaceuticals Inc. It is protected by 6 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 12, 2041. Details of Atzumi's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12102754 | Intranasal delivery devices |
Oct, 2041
(16 years from now) | Active |
| US11744967 | Intranasal delivery devices |
Oct, 2041
(16 years from now) | Active |
| US10758532 | Compositions, devices, and methods for treating or preventing headaches |
Dec, 2039
(14 years from now) | Active |
| US12263162 | Compositions, devices, and methods for treating or preventing headaches |
Dec, 2039
(14 years from now) | Active |
| US11872314 | Pharmaceutical compositions |
Aug, 2037
(12 years from now) | Active |
| US10792253 | Pharmaceutical compositions |
Aug, 2037
(12 years from now) | Active |
FDA has granted several exclusivities to Atzumi. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Atzumi, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Atzumi.
Exclusivity Information
Atzumi holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Atzumi's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 30, 2028 |
US patents provide insights into the exclusivity only within the United States, but Atzumi is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Atzumi's family patents as well as insights into ongoing legal events on those patents.
Atzumi's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Atzumi's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 12, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Atzumi Generic API suppliers:
Dihydroergotamine Mesylate is the generic name for the brand Atzumi. 11 different companies have already filed for the generic of Atzumi, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Atzumi's generic
Alternative Brands for Atzumi
There are several other brand drugs using the same active ingredient (Dihydroergotamine Mesylate) as Atzumi. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Amneal |
| |
| Impel Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Dihydroergotamine Mesylate, Atzumi's active ingredient. Check the complete list of approved generic manufacturers for Atzumi
About Atzumi
Atzumi is a drug owned by Satsuma Pharmaceuticals Inc. Atzumi uses Dihydroergotamine Mesylate as an active ingredient. Atzumi was launched by Satsuma Pharms in 2025.
Approval Date:
Atzumi was approved by FDA for market use on 30 April, 2025.
Active Ingredient:
Atzumi uses Dihydroergotamine Mesylate as the active ingredient. Check out other Drugs and Companies using Dihydroergotamine Mesylate ingredient
Dosage:
Atzumi is available in powder form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 5.2MG BASE | POWDER | Prescription | NASAL |